China Biologic Products (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Separately, BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $137.50.
Several large investors have recently bought and sold shares of CBPO. Schroder Investment Management Group raised its stake in shares of China Biologic Products by 86.5% in the third quarter. Schroder Investment Management Group now owns 1,016,092 shares of the biopharmaceutical company’s stock valued at $92,799,000 after acquiring an additional 471,416 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of China Biologic Products by 62.9% in the third quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock valued at $66,790,000 after acquiring an additional 279,420 shares during the last quarter. Comgest Global Investors S.A.S. raised its position in China Biologic Products by 135.0% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock worth $32,872,000 after purchasing an additional 204,649 shares during the last quarter. New Silk Road Investment PTE Ltd. bought a new position in China Biologic Products in the 3rd quarter worth approximately $17,476,000. Finally, Bank of New York Mellon Corp raised its position in China Biologic Products by 30.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock worth $70,380,000 after purchasing an additional 176,325 shares during the last quarter. Institutional investors own 52.34% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.